Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation on Sangamo Therapeutics and its much-anticipated peek at results from a genome-editing trial. Then we talk about President Trump’s plan to change how often public companies have to spill their guts and what it could mean for biotech. Greg Yap, a partner at Menlo Ventures, joins us to dish on the red flags that dissuade him from a potential biotech investment, and we embark on a lightning round with appearances by bad cholesterol, CAR-T, and a diagnostic menstrual pad.